Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128428 | 0.88 | CA12 (0.40) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL10288678 | 0.86 | PTGS2 (0.37) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL16301784 | 0.74 | L3MBTL1 (0.39) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL7901543 | 0.73 | LMNA (0.33) | PTGS2MEN1KMT2A | |
| SCHEMBL6128427 | 0.72 | CA12 (0.35) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL6128423 | 0.72 | ALDH1A1 (0.38) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL6128430 | 0.72 | MAPT (0.43) | TSHRFAAHMGLLKMT2ATDP1 | |
| SCHEMBL6128414 | 0.70 | MAPT (0.41) | TSHRFAAHMGLLABCB1KMT2A | |
| SCHEMBL6560660 | 0.70 | NPC1 (0.39) | PTGS2TP53MEN1KMT2A | |
| SCHEMBL1572504 | 0.70 | ALDH1A1 (0.45) | PTGS2TP53TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160002183-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002183-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TECR, TAOK1, TET1 | PTGS2 1884/4885CA12 4583/4885CA1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.